18.88 0.67 (3.68%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 23.72 | 1-year : | 27.7 |
Resists | First : | 20.3 | Second : | 23.72 |
Pivot price | 17.85 | |||
Supports | First : | 17.7 | Second : | 16.1 |
MAs | MA(5) : | 17.32 | MA(20) : | 18.1 |
MA(100) : | 16.75 | MA(250) : | 18.1 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 53.2 | D(3) : | 30.1 |
RSI | RSI(14): 57.3 | |||
52-week | High : | 25.46 | Low : | 12.94 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RCUS ] has closed below upper band by 22.2%. Bollinger Bands are 1.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 19.11 - 19.18 | 19.18 - 19.24 |
Low: | 17.99 - 18.08 | 18.08 - 18.15 |
Close: | 18.74 - 18.86 | 18.86 - 18.97 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Wed, 27 Mar 2024
Arcus Biosciences (NYSE:RCUS) Shares Up 7.6% - MarketBeat
Wed, 27 Mar 2024
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Wed, 27 Mar 2024
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $41.25 - MarketBeat
Wed, 27 Mar 2024
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases - Yahoo Movies Canada
Mon, 25 Mar 2024
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by American Century Companies Inc. - Defense World
Wed, 20 Mar 2024
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 91 (M) |
Shares Float | 54 (M) |
Held by Insiders | 41.1 (%) |
Held by Institutions | 59.9 (%) |
Shares Short | 7,680 (K) |
Shares Short P.Month | 7,000 (K) |
EPS | -4.16 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 6.11 |
Profit Margin | -262.4 % |
Operating Margin | -293.6 % |
Return on Assets (ttm) | -17.5 % |
Return on Equity (ttm) | -54.9 % |
Qtrly Rev. Growth | -8.9 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 1.28 |
EBITDA (p.s.) | -3.66 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -306 (M) |
Levered Free Cash Flow | -188 (M) |
PE Ratio | -4.55 |
PEG Ratio | 0 |
Price to Book value | 3.08 |
Price to Sales | 14.66 |
Price to Cash Flow | -5.61 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |